The circ_CDR1as can also enhance resistance to cisplatin-based chemotherapeutic drugs in non-small cell lung cancer (NSCLC) by targeting the miR-641/HOXA9 axis35. Here, HOXA9 is linked to non-small cell lung carcinoma.